The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
June 24, 2024
View Complete Issue         Table of Contents 2019 
Tisotumab Vedotin (Tivdak) for Cervical Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tisotumab Vedotin (Tivdak) for Cervical Cancer (online only)
June 24, 2024 (Issue: 1705)
Tisotumab vedotin-tftv (Tivdak – Seagen/Genmab), a tissue factor-directed antibody and microtubule inhibitor conjugate, has received full approval from the FDA for treatment of recurrent or metastatic cervical cancer that progressed on or after...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tisotumab Vedotin (Tivdak) for Cervical Cancer (online only)
Article code: 1705g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.